These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 38711824)

  • 1. Long-Term Follow-Up of Patients Undergoing Thalidomide Therapy for Transfusion-Dependent β-Thalassaemia: A Single-Center Experience.
    Zhu W; He Y; Huang M; Fu S; Liu Z; Wang X; Li Z; Li X; Chen J; Li Y
    Int J Gen Med; 2024; 17():1729-1738. PubMed ID: 38711824
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thalidomide for Patients with β-Thalassemia: A Multicenter Experience.
    Yang K; Wu Y; Zhou Y; Long B; Lu Q; Zhou T; Wang L; Geng Z; Yin X
    Mediterr J Hematol Infect Dis; 2020; 12(1):e2020021. PubMed ID: 32395210
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term clinical efficacy and safety of thalidomide in patients with transfusion-dependent β-thalassemia: results from Thal-Thalido study.
    Ali Z; Ismail M; Rehman IU; Rani GF; Ali M; Khan MTM
    Sci Rep; 2023 Aug; 13(1):13592. PubMed ID: 37604857
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of Thalidomide Treatment in Children With Transfusion Dependent β-Thalassemia: A Retrospective Clinical Study.
    Li X; Hu S; Liu Y; Huang J; Hong W; Xu L; Xu H; Fang J
    Front Pharmacol; 2021; 12():722502. PubMed ID: 34456732
    [No Abstract]   [Full Text] [Related]  

  • 5. Comparison of efficacy and safety of thalidomide vs hydroxyurea in patients with Hb E-β thalassemia - a pilot study from a tertiary care Centre of India.
    Jain M; Chakrabarti P; Dolai TK; Ghosh P; Mandal PK; Baul SN; De R
    Blood Cells Mol Dis; 2021 May; 88():102544. PubMed ID: 33610115
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of thalidomide in patients with transfusion-dependent β-thalassemia: a randomized clinical trial.
    Chen JM; Zhu WJ; Liu J; Wang GZ; Chen XQ; Tan Y; Xu WW; Qu LW; Li JY; Yang HJ; Huang L; Cai N; Wang WD; Huang K; Xu JQ; Li GH; He S; Luo TY; Huang Y; Liu SH; Wu WQ; Lu QY; Zhou MG; Chen SY; Li RL; Hu ML; Huang Y; Wei JH; Li JM; Chen SJ; Zhou GB
    Signal Transduct Target Ther; 2021 Nov; 6(1):405. PubMed ID: 34795208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with combination of hydroxyurea and low-dose thalidomide in transfusion-dependent beta thalassemia patients.
    Bhurani D; Kapoor J; Yadav N; Khushoo V; Agrawal N; Ahmed R; Arora JS; Mehta P
    Ann Hematol; 2021 Jun; 100(6):1417-1427. PubMed ID: 33811502
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Efficacy of Thalidomide and Hydroxyurea Combination in Beta Thalassemia Patients.
    Garg A; Patel K; Shah K; Trivedi D; Raj A; Yadav R; Shah S
    Indian J Hematol Blood Transfus; 2023 Jan; 39(1):85-89. PubMed ID: 36699430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase 2 Randomized Controlled Trial of Single-Agent Hydroxyurea Versus Thalidomide Among Adult Transfusion Dependent β Thalassemia Patients.
    Bhattacharjee U; Khadwal A; Shafiq N; Lad D; Sharma P; Das R; Shukla P; Jain A; Prakash G; Malhotra P
    Indian J Hematol Blood Transfus; 2023 Apr; 39(2):266-275. PubMed ID: 36620489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia.
    Chandra J; Parakh N; Sidharth ; Singh N; Sharma S; Goel M; Pemde H
    Indian Pediatr; 2021 Jul; 58(7):611-616. PubMed ID: 34315832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Promising Response to Thalidomide in Symptomatic β-Thalassemia.
    Yassin AK
    Indian J Hematol Blood Transfus; 2020 Apr; 36(2):337-341. PubMed ID: 32425386
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating the Efficacy and Safety of Thalidomide for Treating Patients With
    Lu Y; Wei Z; Yang G; Lai Y; Liu R
    Front Pharmacol; 2021; 12():814302. PubMed ID: 35087410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thalidomide and Hydroxyurea in Transfusion-Dependent Thalassemia: Efficacy, Safety Profile and Impact on Quality of Life.
    Bhattacharjee S; Ghosh S; Shaw J; Bhattacharjee S; Bhattacharyya M
    Hemoglobin; 2024 May; 48(3):161-168. PubMed ID: 39092801
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thalidomide induces haematologic responses in patients with β-thalassaemia.
    Chen J; Zhu W; Cai N; Bu S; Li J; Huang L
    Eur J Haematol; 2017 Nov; 99(5):437-441. PubMed ID: 28850716
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The association of HBG2, BCL11A, and HBS1L-MYB polymorphisms to thalidomide response in Chinese β-thalassemia patients.
    Yang K; Wu Y; Ma Y; Xiao J; Zhou Y; Yin X
    Blood Cells Mol Dis; 2020 Sep; 84():102442. PubMed ID: 32387854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term safety and erythroid response with luspatercept treatment in patients with β-thalassemia.
    Piga A; Longo F; Gamberini MR; Voskaridou E; Ricchi P; Caruso V; Pietrangelo A; Zhang X; Shetty JK; Attie KM; Tartaglione I
    Ther Adv Hematol; 2022; 13():20406207221134404. PubMed ID: 36505885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical trial on the effects of thalidomide on hemoglobin synthesis in patients with moderate thalassemia intermedia.
    Ren Q; Zhou YL; Wang L; Chen YS; Ma YN; Li PP; Yin XL
    Ann Hematol; 2018 Oct; 97(10):1933-1939. PubMed ID: 29931453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the combination therapy of hydroxyurea and thalidomide in β-thalassemia.
    Ansari SH; Ansari I; Wasim M; Sattar A; Khawaja S; Zohaib M; Hussain Z; Adil SO; Ansari AH; Ansari UH; Farooq F; Masqati NU
    Blood Adv; 2022 Dec; 6(24):6162-6168. PubMed ID: 35477175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Foetal haemoglobin inducers for reducing blood transfusion in non-transfusion-dependent beta-thalassaemias.
    Foong WC; Loh CK; Ho JJ; Lau DS
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD013767. PubMed ID: 36637054
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Predictors of Hematologic Responses in Patients with Non-Transfusion-Dependent β-Thalassemia Receiving Thalidomide Therapy].
    Yang K; Yin XL; Liu XD; Hua F; Peng W; Li L; Chen K; Zhang J; Luo S; Xiao J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Oct; 30(5):1519-1526. PubMed ID: 36208259
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.